September 17, 2019
Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The study found that, in those with high-cholesterol and major histocompatibility complex class II (MHCII) cells, treating atherosclerosis with immunotherapy may increase cardiovascular risk, demonstrating the immune nature of atherosclerosis.
January 30, 2019
CardioVax, a privately held, clinical-stage biopharmaceutical company developing novel antibody therapeutics for inflammatory diseases, announced today that it has changed its name to Abcentra.